CURE

Sac-TMT Plus Keytruda Extends Progression-Free Survival in PD-L1+ NSCLC

OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...
Cure Today

Postsurgical Keytruda Has Little Impact on Quality of Life in Melanoma

Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
FiercePharma

Merck's Keytruda flunks pivotal studies in early-stage lung and skin cancers

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...
Nasdaq

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...